Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | PPARA | Q07869 | 4/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11639815 | 0.95 | CYP1A2 (0.53) | CYP1A2CYP3A4PPARAABCB11TSHR | |
| SCHEMBL11722923 | 0.84 | CYP1A2 (0.59) | CYP1A2CYP3A4PPARAABCB11TSHR | |
| Eniclobrate SCHEMBL2110877 | 0.83 | OPRK1 (0.67) | CYP1A2CYP3A4PPARAABCB11TSHR | |
| SCHEMBL11638335 | 0.82 | OPRK1 (0.55) | CYP1A2CYP3A4PPARAABCB11TSHR | |
| SCHEMBL11716168 | 0.81 | CYP1A2 (0.55) | CYP1A2CYP3A4PPARACYP2C19CYP2C9 | |
| Etofibrate SCHEMBL8168409 | 0.80 | L3MBTL1 (0.55) | CYP1A2CYP3A4PPARAABCB11TSHR | |
| Etofibrate SCHEMBL29801484 | 0.80 | L3MBTL1 (0.55) | CYP1A2CYP3A4PPARAABCB11TSHR | |
| Etofibrate SCHEMBL3122 | 0.80 | L3MBTL1 (0.55) | CYP1A2CYP3A4PPARAABCB11TSHR | |
| SCHEMBL11431131 | 0.79 | PPARA (0.62) | CYP1A2CYP3A4PPARAABCB11TSHR | |
| Etofibrate SCHEMBL1649349 | 0.79 | L3MBTL1 (0.54) | CYP1A2CYP3A4PPARAABCB11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | claimed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | claimed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | claimed |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-02-23 | — | — | US | claimed |
| EP-4135691-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-02-22 | — | — | EP | claimed |
| EP-0687172-B1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 2002-12-04 | — | — | EP | claimed |
| US-6211207-B1 | ANTIDIABETIC AGENTS AND INSULIN SENSITIVITY ENHANCER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| US-6211206-B1 | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| US-6207178-B1 | STABLE SUSPENSION | KABI PHARMACIA AB (SE) | 2001-03-27 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6133293-A | INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN THE MECHANISM OF ACTION; POTENT DEPRESSIVE EFFECT ON DIABETIC HYPERGLYCEMIA; 2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5785976-A | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | PHARMACIA & UPJOHN AB (SE) | 1998-07-28 | — | — | US | claimed |
| EP-0687172-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | Pharmacia & Upjohn Aktiebolag (SE) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020072-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 1994-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | CYP1A2 2025/4885CYP3A4 826/4885PPARA 1378/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | CYP1A2 2025/4885CYP3A4 826/4885PPARA 1378/4885 |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | PPARD, NR1H4, PPARG | CYP1A2 397/4885CYP3A4 415/4885PPARA 4/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CYP1A2 1885/4885CYP3A4 822/4885PPARA 1336/4885 |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | PPARD, NR1H4, PPARG | CYP1A2 397/4885CYP3A4 415/4885PPARA 4/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CYP1A2 2025/4885CYP3A4 826/4885PPARA 1378/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CYP1A2 2025/4885CYP3A4 826/4885PPARA 1378/4885 |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CYP1A2 2025/4885CYP3A4 826/4885PPARA 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.